Non-recurring gains and losses

Hong Kong IPO disclosure precedents · 311 companies, 348 items

one-off or non-recurring items that move the results: bargain-purchase gains, disposal gains, large exchange losses, a sharp fall in VAT refunds or grants that swings other income

2023-10-16Prospectus
J&T Global Express Limited极兔速递环球有限公司01519.HK

We had other gains, net of US$26.4 million in 2021 and other losses, net of US$40.2 million in 2022, primarily due to (i) provisions for lawsuits in relation to the restructuring and integration of acquired operations of BEST Express China, and (ii) a foreign exchange loss we recognized in 2022 of US$17.3 million due to fluctuations in exchange rates of local currencies in countries where we operate against U.S. dollars.

Financial Information · p. 369

Our other losses, net, decreased from US$31.7 million for the six months ended June 30, 2022 and to US$43.4 million for the same period in 2023, primarily due to (i) a decrease in provisions for lawsuits arising from pre-acquisition operations of BEST Express China, and (ii) a decrease in foreign exchange loss we recognized in 2023 of US$12.4 million, offset by an increase in net losses on disposal of property, plant and equipment.

Financial Information · p. 365
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-09-28Prospectus
Luyuan Group Holding (Cayman) Limited绿源集团控股(开曼)有限公司02451.HK

Our other gains – net increased significantly by 199.1% from RMB11.2 million in 2021 to RMB33.6 million in 2022, primarily due to (i) gains from disposal of Fujian Yizhou of RMB6.8 million, (ii) an increase in gains on disposal of property, plant and equipment of RMB2.5 million as a result of the disposal of a mould used for our regular production, (iii) gains from disposal of LYVA COMPANY LIMITED of RMB0.3 million, (iv) exchange gains of RMB1.1 million attributable to the appreciation of RMB and (v) an increase in fair value changes on financial assets at FVTPL of RMB4.7 million, which represented gains from our investments in certificate of deposits, wealth management products and structured deposits.

Financial Information · p. 363

Gains from disposal of associated companies derived from the disposal of Fujian Yizhou and Hangzhou Guangyang in 2022.

Financial Information · p. 353
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-09-28Prospectus
Shiyue Daotian Group Co., Ltd.十月稻田集团股份有限公司09676.HK

Our other net income increased significantly from RMB7.0 million in 2020 to RMB49.3 million in 2021, primarily due to the significant increase in government grants, which increased from RMB7.2 million in 2020 to RMB44.0 million in 2021.

Financial Information · p. 315

Our other net income decreased by 44.4% from RMB49.3 million in 2021 to RMB27.4 million in 2022, primarily due to the decrease in the government grants, as we received more government grants in relation to the China Good Grain and Oil project in 2021.

Financial Information · p. 311

A significant portion of government grants we received during the Track Record Period came from China Good Grain and Oil project, which was initiated by local governments to promote local agricultural industry value chain and to encourage industry players to enhance production efficiency.

Financial Information · p. 300
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-09-25Prospectus
Tian Tu Capital Co., Ltd.深圳市天图投资管理股份有限公司01973.HK

We recorded net profit of RMB1,057.9 million, RMB719.8 million, and RMB532.9 million in 2020, 2021 and 2022, including one-off gains from the deconsolidation of Mengtian Dairy in 2021 and Yoplait China in 2022, which represent the fair value gains on deemed loss of control over them.

Summary · p. 3

We also recognized a one-off gain on its deconsolidation of RMB123.3 million in 2021.

Business · p. 270

We also recognized a one-off gain on its deconsolidation of RMB520.4 million included in the profits attributable to the owners of the Company from discontinued operations in 2022, which represents the fair value gains on deemed loss of control over Yoplait China.

Business · p. 272
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-09-18Prospectus
NEUSOFT XIKANG HOLDINGS INC.东软熙康控股有限公司09686.HK

Our net other losses or gains primarily consist of (i) gains or losses recognized from the disposal of our subsidiaries in 2020, 2021 and 2022 and the three months ended March 31, 2022 and 2023, (ii) gains or losses recognized from disposal of fixed assets such as medical equipment, electronic equipment and office equipment, and (iii) net foreign exchange losses, mainly relating to the fluctuations of foreign exchange rates affecting our U.S. dollar-denominated assets and liabilities.

Financial Information · p. 404

We recorded net other losses of RMB1.8 million in 2022, changed from net other gains of RMB20.9 million in 2021, primarily because the net foreign exchange losses increased due to the fluctuation of foreign exchange rates in 2022.

Financial Information · p. 414

The increase in our adjusted net loss (non-HKFRS measure) in 2022 was mainly due to a slight decrease in our gross profit and an increase in our net foreign exchange losses, despite decreases in our total operating expenses excluding share-based compensation expenses in 2022 compared to 2021.

Financial Information · p. 393
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-09-18Prospectus
ZX Inc.中旭未来09890.HK

Our other income and gains increased significantly from RMB87.4 million for the four months ended April 30, 2022 to RMB396.6 million for the four months ended April 30, 2023, primarily due to an increase of RMB327.0 million in investment income from financial assets at FVTPL, which we recognized from the sale of equity interests in a listed company.

Financial Information · p. 422
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-09-14Prospectus
TUHU Car Inc.途虎养车股份有限公司09690.HK

We recorded loss on repurchase of convertible redeemable preferred shares of RMB363.9 million in 2019, which represents our one-off repurchase of convertible redeemable preferred shares as a result of withdrawals by certain investors in 2019.

Financial Information · p. 420

The increase was primarily due to the increase in government grants awarded by the local governments to support our operation, partially offset by (i) a RMB48.5 million decrease in the one-off gain recognised from our investment in an associate jointly invested by ExxonMobil through contribution of software from RMB76.5 million in 2020 to RMB28.0 million in 2021, and (ii) a decrease in net foreign exchange gains, primarily because the exchange rate of U.S. dollar against Renminbi experienced relatively large volatility during the same period.

Financial Information · p. 415
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-09-13Prospectus
WUHAN YZY BIOPHARMA CO., LTD.武汉友芝友生物制药股份有限公司02496.HK

Our other income decreased from RMB12.8 million in 2021 to RMB2.6 million in 2022. The decrease was primarily due to (i) the decrease in government grants of RMB9.8 million in 2022 as government grants are non-recurring in nature, subject to the satisfaction of certain conditions each year and (ii) the decrease in income from sales of protein antigen of RMB0.5 million in 2022 as it was an one-off transaction in 2021 based on a technical service agreement with an independent third party.

Financial Information · p. 505

The increase was primarily due to the increase in government grants of RMB5.3 million, which we received from the local government as subsidies for compensating our research and development of our drug candidates.

Financial Information · p. 504
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-09-13Prospectus
LC Logistics, Inc.乐舱物流股份有限公司02490.HK

Our other income and gains increased from RMB9.8 million in 2020 to RMB23.7 million in 2021, primarily due to an increase in (i) gain on disposal of property, plant and equipment from RMB7.8 million in 2020 to RMB18.4 million in 2021 primarily due to the increase in the price of disposed containers caused by the short supply due to COVID-19 pandemic; (ii) gain on disposal of associates from RMB0.1 million in 2020 to RMB3.3 million in 2021, primarily due to the disposal of 45% of equity interest in BAL Bright in December 2021.

Financial Information · p. 380

The significant increase in net profit from 2020 to 2021 was primarily driven by (i) an increase in our gross profit from RMB63.8 million in 2020 to RMB456.8 million in 2021 as a result of the increase in our revenue and gross profit margin, as we commenced self-operated cross-border seaborne transportation service in the first half of 2021; and (ii) an increase in our other income and gains from RMB9.8 million in 2020 to RMB23.7 million in 2021.

Summary · p. 24

Our other income and gains decreased from RMB23.7 million in 2021 to RMB9.5 million in 2022, primarily due to the absence of gain on disposal of property, plant and equipment, gain on disposal of associates and gain on disposal of a subsidiary in 2022, partially offset by an increase in foreign exchange gains from nil in 2021 to RMB6.8 million in 2022 mainly arising from the exchange rate fluctuation when we settled trade receivables in U.S. dollars.

Financial Information · p. 376
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-08-24Prospectus
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.宜明昂科生物医药技术(上海)股份有限公司01541.HK

Net foreign exchange gains or losses mainly represent the exchange gains or losses resulted from the translation of financial assets and liabilities denominated in U.S. dollar at year end exchange rates.

Financial Information · p. 377

(ii) a change from net foreign exchange losses of RMB9.1 million in 2021 to net foreign exchange gains of RMB26.1 million in 2022, in connection with our net financial assets denominated in U.S. dollar, which had appreciated against Renminbi in 2022

Financial Information · p. 385
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-06-30Prospectus
New Media Lab Limited新传企划有限公司01284.HK

Such income represented approximately 7.5% and 38.8% of our revenue and profit for the year ended 31 December 2020, respectively.

Financial Information · p. 240

Such income represented approximately 2.4% and 14.4% of our revenue and profit for and the year ended 31 December 2022, respectively.

Financial Information · p. 240

The decrease was mainly attributable to the government subsidies of approximately HK$16.0 million for the year ended 31 December 2020.

Financial Information · p. 249
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-06-30Prospectus
Star Plus Legend Holdings Limited巨星传奇集团有限公司06683.HK

Our other income increased from RMB234,000 for the year ended December 31, 2021 to RMB21.8 million for the year ended December 31, 2022, mainly due to government grants of RMB16.5 million in relation to (i) financial subsidies from the local government for maintain stability of employees and business during the COVID-19 pandemic; and (ii) a one-off awards from the government for our contribution to the business of Kunshan Huaqiao Economic Development Zone.

Financial Information · p. 427

Governments grants of RMB16.5 million for the year ended December 31, 2022 primarily comprised (i) the financial subsidies received from the Department of Finance in Kunshan for the efforts of maintaining stability of employees and business during the pandemic; and (ii) one-off awards from the government for our contribution to the business of Kunshan Huaqiao Economic Development Zone.

Financial Information · p. 420

Our adjusted net profit (non-HKFRS measure) has increased from RMB69.9 million for the year ended December 31, 2021 to RMB77.2 million for the year ended December 31, 2022, which was primarily attributable to (i) the increase in our other income from government grant and (ii) decrease in our selling and marketing expenses as a result of the restrictions imposed by local government for the prevention of the pandemic.

Financial Information · p. 391
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-06-30Prospectus
Star Plus Legend Holdings Limited巨星传奇集团有限公司06683.HK

For the year ended December 31, 2020, we recorded a settlement sum of RMB9.4 million, in connection with the investment made by an investor, who is an Independent Third Party, in connection with the J-Style Trip season one.

Financial Information · p. 421

As a result, we recorded forfeited deposit of RMB1.6 million as other income for the year ended December 31, 2020.

Financial Information · p. 419

We recorded net other losses of RMB114,000 in 2019 and net other gains of RMB10.3 million in 2020, respectively.

Financial Information · p. 434
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-06-30Prospectus
Star Plus Legend Holdings Limited巨星传奇集团有限公司06683.HK

We recorded other loss of RMB9.6 million for the year ended December 31, 2022, which was primarily attributable to our net foreign exchange losses of RMB9.9 million mainly due to the exchange loss arising from the bank balance held by the offshore subsidiaries which was denominated in RMB as a result of the depreciation of RMB against HK dollars during the period, which was denominated in HK dollars, as a result of the devaluation of RMB to HK dollars during the relevant period.

Financial Information · p. 421

For the year ended December 31, 2022, we recorded other loss of RMB9.6 million, as compared to other gains of RMB4.0 million for the year ended December 31, 2021, which was mainly attributable to the net foreign exchange losses of RMB9.9 million primarily arising from the bank balance held by our offshore subsidiaries which was denominated in RMB as a result of the devaluation of RMB against HK dollars during the period.

Financial Information · p. 428
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-06-29Prospectus
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.四川科伦博泰生物医药股份有限公司06990.HK

We recorded other net income of RMB34.8 million for the year ended December 31, 2021, as compared to other net expenses of RMB4.4 million for the year ended December 31, 2022, which was primarily because we recorded net foreign exchange losses of RMB31.9 million for the year ended December 31, 2022, as compared to net foreign exchange gains of RMB16.9 million for the year ended December 31, 2021, as a result of the fluctuation in exchange rate of Renminbi against U.S. dollars.

Financial Information · p. 517
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-06-28Prospectus
Wise Living Technology Co., Ltd慧居科技股份有限公司02481.HK

Other income decreased by approximately RMB19.8 million or 27.0% from approximately RMB73.6 million for the year ended 31 December 2021 to approximately RMB53.7 million for the year ended 31 December 2022, primarily attributable to the reduction of government grants provided by the relevant local government for our Lanzhou New Area Project.

Financial Information · p. 507

Government grants are not recurring in nature, there are no specific formulae for the determination of the government grants, they were determined by the local government on an incidental basis, and they are not directly related to heat rates.

Financial Information · p. 498
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-06-16Prospectus
Laekna, Inc.来凯医药有限公司02105.HK

Net gain on termination of leases represents the gain we recognized based on the difference between the carrying amount of the right-of-use assets and the lease liabilities and deduction of estimated penalties in relation to a lease agreement on which we have delivered a termination notice to the lessor in 2022.

Financial Information · p. 391

Our other income increased significantly from RMB0.5 million in 2021 to RMB4.8 million in 2022, primarily due to an increase of RMB3.7 million in net gain on termination of leases and an increase of RMB0.4 million in interest income from bank deposits.

Financial Information · p. 399
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-05-31Prospectus
Cutia Therapeutics科笛集团02487.HK

In 2021 and 2022, we recorded gains of RMB0.2 million and RMB81.7 million, respectively.

Financial Information · p. 408

Foreign exchange gains, net | – | 73,979

Financial Information · p. 408

This increase was primarily due to an increase in the bank interest income and net foreign exchange gains in connection with our cash and cash equivalents and time deposits over three months denominated in the U.S. dollars, as a result of the appreciation of the U.S. dollar against RMB.

Financial Information · p. 413
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-05-15Prospectus
Edianyun Limited易点云有限公司02416.HK

Our other income increased from RMB9.6 million for the year ended December 31, 2021 to RMB48.9 million for the year ended December 31, 2022, as certain of our subsidiaries became eligible for additional VAT input deduction.

Financial Information · p. 301

For the year ended December 31, 2022, we had current period VAT payable due to the continued increase in revenue, and therefore, we were eligible for additional VAT input deduction, and consequently recognized additional VAT input deduction.

Financial Information · p. 293
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-05-15Prospectus
Edianyun Limited易点云有限公司02416.HK

During the year ended December 31, 2020, the USD depreciated significantly against RMB, and the amount of our bank balances in USD increased as we owned U.S. dollar-denominated convertible bonds, resulting in a net exchange loss.

Financial Information · p. 294

The change of our recorded net exchange loss to net exchange gain was mainly caused by foreign exchange rate changes.

Financial Information · p. 305
The company's explanation, the adviser's view and the page in the filing: see Matters

Tell us